Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

HIV infection in breast cancer patients from Mozambique: A prospective cohort study


03 May 2019


Poster lunch


Mariana Brandão


Annals of Oncology (2019) 30 (suppl_3): iii65-iii71. 10.1093/annonc/mdz101


M.D.R.A. Brandão1, A. Guisseve2, G. Bata3, G. de Morais3, M. Alberto2, F. Schmitt4, C. Lorenzoni2, S. Tulsidás3, N. Lunet5, C. Carrilho2

Author affiliations

  • 1 Academic Promoting Team, Institut Jules Bordet, 1000 - Brussels/BE
  • 2 Pathology Department, Maputo Central Hospital, Maputo/MZ
  • 3 Oncology Unit, Maputo Central Hospital, Maputo/MZ
  • 4 Pathology Department, Institute of Molecular Pathology and Immunology, Porto/PT
  • 5 Epiunit – Instituto De Saúde Pública, Universidade do Porto, Porto/PT



Breast cancer (BC) burden is increasing among women living with HIV (HIV+). Yet, data regarding epidemiology, BC presentation, treatment, and prognosis is still scarce, especially among HIV+ BC patients (pts) from developing countries.


This prospective cohort included BC patients diagnosed at the Maputo Central Hospital, Mozambique, from Jan-2015 to Mar-2017. Data on demographics, BC risk factors, co-morbidities, treatment, and survival were prospectively collected. Chi2 and t tests were used to compare categorical and continuous variables, respectively. Time-to-event outcomes were estimated using Kaplan-Meier methods. Survival estimates were compared using log-rank test and Cox proportional hazards models. All tests were two-tailed and results were considered significant if p-value was <.05.


Among 205 pts included, 98% were black and 52 (25%) were HIV+. HIV+ pts were younger than HIV- pts (median age: 44.5 vs 51.0 years respectively, p=.002), and most had stage III/IV BC (81% vs 71%, p=.204). Among HIV+ pts, 90% had a CD4+ cells count > 200/μL and 26% were diagnosed at the time of BC. Immunohistochemistry analysis was performed in 152 pts and showed that HIV+ pts had a higher proportion of triple-negative BC (TNBC) compared to HIV- pts (37.5% vs 20.5%, p=.029). Among pts with early BC (EBC), there were no significant differences in local treatments received; yet, HIV+ pts tended to receive a lower chemotherapy (CT) dose-intensity (DI) compared to HIV- pts (DI < 85%: 69.4% vs 50.0%, p=.057). Median overall survival (OS) was 31.0 months (m) in HIV+ pts and 34.0 m in HIV- pts (unadjusted hazard ratio [HR] 1.52, 95% confidence interval [CI] 0.92 – 2.51). In EBC pts, median disease-free survival was 27.0 m in HIV+ pts and 31.0 m in HIV- pts (HR 1.37, 95% CI 0.81-2.31).


Our results show that in Southeast Africa the proportion of HIV+ women among BC pts can be very high. These pts were diagnosed at a younger age and had a significantly higher proportion of TNBC compared to HIV- pts. They tended to receive lower CT DI, and their survival was worse as compared to HIV- pts, although not statistically different. This highlights the need for better understanding BC biology in HIV+ pts and to provide effective cancer care to this underserved population.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Faculty of Medicine, Eduardo Mondlane University, Mozambique.


NIH AORTIC BIG CAT grant (award number 59-210-6-004).


M.D.R.A. Brandão: Research grants to my Institute: Roche, Menarini Silicon Biosystems, Pfizer, Janssen Diagnostics. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings